stockrow
Saturday 7 November 2026
Export ENTA’s income statement to Excel — free account
Enanta Pharmaceuticals, Inc.
ENTA Healthcare Biotechnology
Enanta Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $65.3 million, down 3.42% from fiscal 2024.
- Revenue
- −21.6%
- EPS
- +21.2%
- Free cash flow
- −157.5%
Quarter to June 2026, against a year earlier
11.00
0.92
+9.13%
Follow ENTA
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.91 | 6.77 | 5.30 | 6.50 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(39.36) | (38.75) | (51.25) | (42.53) | |
P/B ratio |
3.95 | 3.58 | 3.15 | 4.20 | |
Price to Tangible BV |
3.95 | 3.58 | 3.15 | 4.20 | |
EV/Sales |
1.02 | 3.99 | 2.93 | 3.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.45) | (18.88) | (25.90) | (6.64) | |
EV/FCF |
(2.07) | (14.49) | (21.13) | (6.35) | |
Quick Ratio |
4.03 | 4.35 | 3.70 | 3.62 | |
Current Ratio |
4.21 | 4.44 | 3.84 | 3.76 | |
Net Debt/EBITDA |
10.46 | 18.58 | 15.84 | 11.81 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.20 | 0.20 | 0.22 | 0.22 | |
Operating CF/Net income |
0.35 | 0.98 | 0.55 | 0.51 | |
Capex/Depreciation |
(4.47) | (0.11) | (0.01) | (0.01) | |
Interest Coverage |
(7.70) | (3.65) | (3.57) | (4.17) | |
Research and Development Expense of Revenue |
157.41% | 112.05% | 113.31% | 154.09% | |
Selling, General and Administrative Expense of Revenue |
64.15% | 48.40% | 55.76% | 65.94% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
26.67% | 20.47% | 21.84% | 25.65% | |
Graham Net Nets |
(0.05) | (0.01) | (0.05) | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(32.00%) | (20.29%) | (20.51%) | (16.53%) | |
Free Cash Flow Yield |
(12.60%) | (4.07%) | (2.62%) | (8.71%) | |
Revenue per Share |
0.71 | 0.65 | 0.59 | 0.49 | |
Operating CF per Share |
(0.30) | (0.41) | (0.25) | (0.34) | |
Capex per Share |
(0.07) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.41) | (0.25) | (0.34) | |
Cash per Share |
8.85 | 6.46 | 5.64 | 6.51 | |
Shareholders Equity per Share |
3.03 | 4.40 | 4.01 | 3.47 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.03 | 4.40 | 4.01 | 3.47 | |
Free Cash Flow |
(7.95) | (11.84) | (7.17) | (9.98) | |
Working Capital |
155.78 | 153.96 | 131.97 | 149.45 | |
Capital Expenditures |
(1.46) | (0.14) | (0.01) | (0.01) | |
Net Current Asset Value |
(11.68) | (4.23) | (19.70) | 7.82 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.10 | 0.01 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
22.76 | 24.33 | 24.23 | 7.45 | |
Average Payables |
4.98 | 3.31 | 4.56 | 3.42 | |
Average Assets |
328.69 | 339.07 | 318.85 | 298.95 | |
Average Common Equity |
96.77 | 119.20 | 105.06 | 90.17 |
Columns are period end dates